The new company, YL Biologics, Tokyo, will develop biosimilars such as Embrel (Etanercept), an anti-TNF used as antirheumatic agent.
Yoshindo Pharmaceuticals news release, April 24, 2014
The new company, YL Biologics, Tokyo, will develop biosimilars such as Embrel (Etanercept), an anti-TNF used as antirheumatic agent.
Yoshindo Pharmaceuticals news release, April 24, 2014
This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.
Accept or Deny